T1	Condition 49 64	Hunter syndrome
T2	Condition-Name 49 64	Hunter syndrome
E1	Condition:T1 Name:T2
T3	Life-Stage-And-Gender 70 74	Male
A1	Life-Stage-And-Gender-Type T3 male
T4	Procedure 296 309	contraception
T5	Procedure-Name 296 309	contraception
E4	Procedure:T4 Name:T5
T6	Procedure 398 409	bronchotomy
T7	Procedure-Name 398 409	bronchotomy
E6	Procedure:T6 Name:T7 Temporality:E27
T10	Life-Stage-And-Gender 768 774	Female
A2	Life-Stage-And-Gender-Type T10 female
T11	Eq-Operator 89 90	≥
A3	Eq-Operator-Value T11 GTEQ
T12	Eq-Operator 632 638	within
A4	Eq-Operator-Value T12 LTEQ
T13	Eq-Temporal-Unit 642 646	days
A5	Eq-Temporal-Unit-Value T13 day
T14	Age 82 85	age
E9	Age:T14 Eq-Comparison:E10
T15	Eq-Value 91 92	5
T18	Eq-Value 639 641	30
T20	Eq-Comparison 89 92	≥ 5
E10	Eq-Comparison:T20 Operator:T11 Value:T15
T21	Eq-Comparison 632 646	within 30 days
E11	Eq-Comparison:T21 Operator:T12 Temporal-Unit:T13 Value:T18
T22	And 75 77	at
E2	And:T22 Arg:T3 Arg2:E9
T24	Assertion 285 295	Consent to
E5	Assertion:T24 Asserted:E4
A6	Assertion-Type-Value E5 hypothetical
T17	Drug 356 381	iduronate-2-sulfatase ERT
E7	Drug:T17 Name:T8
T8	Drug-Name 356 381	iduronate-2-sulfatase ERT
T9	Procedure 411 436	bone marrow trasplanation
E8	Procedure:T9 Name:T25
T25	Procedure-Name 411 436	bone marrow trasplanation
T26	Procedure 441 466	cord blood transplanation
E12	Procedure:T26 Name:T27
T27	Procedure-Name 441 466	cord blood transplanation
T28	Or 438 440	or
E13	Or:T28 Arg:E8 Arg2:E12
T29	Condition 479 495	hypersensitivity
E14	Condition:T29 Name:T30
T30	Condition-Name 479 495	hypersensitivity
T31	Drug 553 560	product
E15	Drug:T31 
T32	Drug 623 631	products
E16	Drug:T32 Temporality:E17
T33	Eq-Comparison 575 582	planned
E17	Eq-Comparison:T33 Temporal-Period:T34
T34	Eq-Temporal-Period 575 582	planned
A7	Eq-Temporal-Period-Value T34 future
T35	Eq-Comparison 566 571	Prior
E18	Eq-Comparison:T35 Temporal-Period:T36
T36	Eq-Temporal-Period 566 571	Prior
A8	Eq-Temporal-Period-Value T36 past
T37	Or 572 574	or
E19	Or:T37 Arg:E18 Arg2:E17
T38	Procedure 654 663	treatment
E20	Procedure:T38 Temporality:E11
T39	Temporal-Connection 647 653	before
E21	Temporal-Connection:T39 Arg:E11 Arg2:E16
A9	Temporal-Connection-Type-Value E21 before
T40	Drug 689 696	product
E22	Drug:T40 
R2	Using Arg1:E20 Arg2:E22	
T42	Temporal-Connection 714 720	duirng
E23	Temporal-Connection:T42 Arg:E22 Arg2:E26
A10	Temporal-Connection-Type-Value E23 during
T19	Observation 756 761	6-MWT
E24	Observation:T19 Name:T43
T43	Observation-Name 756 761	6-MWT
T44	Negation 738 744	Unable
E25	Negation:T44 Negates:E24
T41	Study 726 731	study
E26	Study:T41 
T45	Eq-Comparison 387 394	History
E27	Eq-Comparison:T45 Temporal-Period:T46
T46	Eq-Temporal-Period 387 394	History
A11	Eq-Temporal-Period-Value T46 past
T47	Eq-Comparison 335 340	Prior
E28	Eq-Comparison:T47 Temporal-Period:T48
T48	Eq-Temporal-Period 335 340	Prior
A12	Eq-Temporal-Period-Value T48 past
T16	Procedure 341 350	treatment
E3	Procedure:T16 Temporality:E28
R3	Using Arg1:E3 Arg2:E7	
T23	Study 538 552	invetigational
E29	Study:T23 Study-Of:E15
R1	Caused-By Arg1:E14 Arg2:E15	
T49	Study 607 622	investigational
E30	Study:T49 Study-Of:E16
T50	Study 673 688	investigational
E31	Study:T50 Study-Of:E22
T51	Observation 128 133	6-MWT
E32	Observation:T51 Name:T52
T52	Observation-Name 128 133	6-MWT
T53	Assertion 738 744	Unable
E33	Assertion:T53 Asserted:E25
A13	Assertion-Type-Value E33 hypothetical
